Centre National de Référence S. aureus, Hôpital Erasme - Université Libre de Bruxelles (ULB), 808 Route de Lennik, Bruxelles, Belgium.
MRSA Knowledge Center, Hvidovre Hospital, Kettegard Alle 30, Hvidrove, Denmark.
J Antimicrob Chemother. 2018 Oct 1;73(10):2662-2666. doi: 10.1093/jac/dky260.
We present the results of two European external quality assessments (EQAs) conducted in 2014 and 2016 under the auspices of the Study Group on Staphylococci and Staphylococcal Infections of ESCMID. The objective was to assess the performance of participating centres in characterizing Staphylococcus aureus using their standard in-house phenotypic and genotypic protocols.
A total of 11 well-characterized blindly coded S. aureus (n = 9), Staphylococcus argenteus (n = 1) and Staphylococcus capitis (n = 1) strains were distributed to participants for analysis. Species identification, MIC determination, antimicrobial susceptibility testing, antimicrobial resistance and toxin gene detection and molecular typing including spa typing, SCCmec typing and MLST were performed.
Thirteen laboratories from 12 European countries participated in one EQA or both EQAs. Despite considerable diversity in the methods employed, good concordance (90%-100%) with expected results was obtained. Discrepancies were observed for: (i) identification of the S. argenteus strain; (ii) phenotypic detection of low-level resistance to oxacillin in the mecC-positive strain; (iii) phenotypic detection of the inducible MLSB strain; and (iv) WGS-based detection of some resistance and toxin genes.
Overall, good concordance (90%-100%) with expected results was observed. In some instances, the accurate detection of resistance and toxin genes from WGS data proved problematic, highlighting the need for validated and internationally agreed-on bioinformatics pipelines before such techniques are implemented routinely by microbiology laboratories. We strongly recommend all national reference laboratories and laboratories acting as referral centres to participate in such EQA initiatives.
我们介绍了 2014 年和 2016 年在 ESCMID 葡萄球菌和葡萄球菌感染研究小组的主持下进行的两项欧洲外部质量评估 (EQA) 的结果。目的是评估参与中心使用其标准的表型和基因型方案来表征金黄色葡萄球菌的表现。
共向参与者分发了 11 株经过良好特征描述的盲法编码金黄色葡萄球菌 (n=9)、金黄色葡萄球菌 (n=1) 和头状葡萄球菌 (n=1) 菌株进行分析。进行了物种鉴定、MIC 测定、抗菌药物敏感性测试、抗菌药物耐药性和毒素基因检测以及分子分型,包括 spa 分型、SCCmec 分型和 MLST。
来自 12 个欧洲国家的 13 个实验室参加了一项或两项 EQA。尽管所使用的方法存在很大差异,但仍获得了与预期结果非常一致的结果 (90%-100%)。观察到的差异包括:(i) 金黄色葡萄球菌菌株的鉴定;(ii) mecC 阳性菌株对苯唑西林的低水平耐药性的表型检测;(iii) 可诱导 MLSB 菌株的表型检测;和 (iv) 基于 WGS 的一些耐药性和毒素基因检测。
总体而言,观察到与预期结果非常一致的结果 (90%-100%)。在某些情况下,从 WGS 数据准确检测耐药性和毒素基因证明存在问题,这突出表明在微生物学实验室常规实施此类技术之前,需要经过验证和国际认可的生物信息学管道。我们强烈建议所有国家参考实验室和作为转诊中心的实验室参加此类 EQA 计划。